Retatrutide at a glance
| Detail | What the sources say |
|---|---|
| Developer | Eli Lilly |
| How it works | One molecule activating GIP, GLP-1 and glucagon receptors |
| Stage | Phase 3 (TRIUMPH programme) |
| Next step | Lilly plans an FDA application in the first quarter of 2027 (Q2 2026 report) |
| Approved? | No, in any country, as of the update date |
| Research-market products | The FDA has warned sellers of retatrutide labelled “for research purposes” |
From the sources to the app
| What the sources say | What PepLabo does with it |
|---|---|
| There is no FDA label, so no official schedule, missed-dose rule or storage rule exists [4]. | PepLabo fills in nothing. Every amount, schedule and use period comes from you or your study team. |
| Products sold “for research purposes” are not FDA-approved, and their quality is unknown [4]. | PepLabo records what you enter, including lot and expiry, but it cannot verify a product. |
| Phase 2 results were published in 2023 [2]; the phase 3 programme has reported [3]. | The library entry lists the status with sources and dates, so you can see what has changed. |
What PepLabo does and does not do
| PepLabo does | PepLabo does not |
|---|---|
| Record each dose with the date, time and amount you enter, and the site for injections | Suggest a dose, a schedule change or a medicine |
| Remind you 15 minutes before, at the dose time, and 30 minutes after a missed dose | Tell you what to do after a missed dose; the leaflet and your prescriber do |
| Put check-ins, weight and doses on one timeline | Interpret symptoms or judge progress |
| Keep your records on your phone, with no account needed to track | Use analytics, advertising or tracking SDKs, or write to Apple Health |
| Create a PDF of your dose log for your clinician (Pro) | Replace your clinician or pharmacist |
